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Objectives: Essential Hypertension (EHT) is described as sailent killer as it is 
almost symptomless.However mild symptoms like headache, loss of sleep, gid-
diness, redness in the eye and restlessness comprise of morbidity. In this study 
Gandharvahasthadi Kashayam (GK) consisting of polyherbal meidicines was studied 
in the manAgement of EHT. MethOds: The case control study was adminsitred 
for 30 patients who were diagonosed with EHT .For one month, Each patient was 
administred 15 ml bid with GK, half an hour before food. Systolic Blood Pressure 
(SBP) was in the range of 140-160 and Diastolic(DBP) was 90 to 100 were inclluded in 
the study. The morbidity was scored by history taking. Results: After one month 
The SBP was 126 -136 and DBP 80- 86; the headache was relived in in 15 patients, 
improvement in loss of sleep reported in 22 patients, redness in the eye was relived 
2 patient out of 5 . 20 patients expressed relief rom restlessness. cOnclusiOns: 
The GK is found to control SBP and DBP in all patients studied. In addition it has 
shown improvement in morbidity of EHT patients.
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Objectives: The purpose of this study is to examine whether there is quality dif-
ferences among AMI patients by severity of cases and by payers status. MethOds: 
The Study examined the outcome differences of acute myocardial infarction (AMI) 
at the National Cardiovascular Center (NCC) Harapan Kita, Jakarta, Indonesia. This 
study analyzed medical records of patients with AMI during the period of January 
1, 2009 until December 31, 2012. Results: The study found 5,472 patients with AMI 
consisting of 81.5% males and 18.5% females with the mean age of 56.3 years (range 
between 21-97 years vs. 26-96 years). Most of the patients were from Jakarta (51%). 
On severity levels, 46% patients were in severity level I, 47.7% severity level II, and 
5.9% level III. More than half (54.6%) patients were treated with intervention (PTCA) 
or surgical procedures (CABG), while 44.4% patients were treated conventionally. We 
found that 43.7% of patients were covered by public insurance, and only 2.9% were 
on Medicaid. The average length of stays was 7.7 days and 87.8% were discharged in 
a good recovery. There was no difference in quality of treatment by difference payers 
or payment system although there was significant discrepancies in charges among 
difference payers. cOnclusiOns: It is concluded that the doctors provided the 
same quality of services among AMI patients, regardless of payers’ status or charges. 
There was no difference in outcome of care among different payers.
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Objectives: Calcium channel blockers are drugs of first choice in the treatment 
of hypertension. The aim of this study was to analyze the consumption of calcium 
channel blockers in Serbia in the period from 2008 to 2012 year. MethOds: The 
data about the use of drugs were taken from the Agency for Drugs and Medical 
Devices of the Serbia. Results: The most frequently used drug from this group 
with mainly vascular effects was amlodipine. During this observed five years the 
consumption of amlodipine is in steadily increased. In 2008. it was 32.00 DDD/1000 
inh/day, at the end of 2011. year the consumption reached it maximum and it 
ranged 72.97 DDD/1000 inh/day. In 2012. the consumption of this drug records 
small fall, and it ranged 66.64 DDD/1000 inh/day.On the second place in drug 
consumption in the same group of drugs was nifedipine. Contrary to amlodipine, 
nifedipine records a decline in consumption. From the calcium channel blockers 
with direct cardiac effects the most frequently used drugs were verapamil and 
diltiazem. The consumption of verapamil in the observed years was uneven. At 
the and of 2012. consumption of this drug was reduced by 50%. The consumption 
of diltiazem in observed five years is in constantly decreasing. cOnclusiOns: 
In Serbia, in the observed period the consumption of calcium channel blockers 
been uneven. In 2011. and 2012. the consumption of calcium channel blockers 
marks a positive trend. This research was supported by Provincial Secretariat 
for Science and Technological Development, Autonomous Province of Vojvodina 
project No 114-451-2458/2011 and by Ministry of Science, Republic of Serbia, pro-
ject no 41012.
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Objectives: Beta blocking agents are drugs of first choice in the treatment of 
hypertension. The aim of this study was to analyze the consumption of beta block-
ing agents in Serbia in the period from 2008 to 2012 year. MethOds: The data 
about the use of drugs were taken from the Agency for Drugs and Medical Devices 
of the Serbia. Results: During the observed period in Serbia the consumption 
of selective beta blocking agents were dominant. The most frequently used drug 
from this group was metoprolol. During this five years the consumption of meto-
prolol is in steadily decreased. In 2008. it was 33.32 DDD/1000 inh/day, at the end 
of 2012. year the consumption was 22.09 DDD/1000inh/day. On the second place 
in drug consumption in the same group of drugs was atenolol, but only in 2008. 
From 2009-2012, atenolol records a decline in consumption and bisoprolol takes 
the second place in drug consumption in that period. At the beginning of 2008. 
consumption of this drug was small, gradually grew and reached its maximum 
in 2012, and it ranged 20.64 DDD/1000inh/day. From the unselective beta blocking 
agents the most frequently used was propranolol and his consumption in the 
observed years was constant. cOnclusiOns: In Serbia, in the observed period 
the consumption of beta blocking agents been mostly constant. From all drugs in 
group of beta blocking agents the most frequently used are metoprolol, atenolol, 
follow-up duration and catheter, so uncertainty may exist regarding overall therapy 
effectiveness. The objective of this analysis is to conduct a systematic review and 
direct meta-analysis of relevant RDN studies to provide a more powerful estimate of 
the true effect size to inform clinical decisions and economic evaluations. MethOds: 
RDN publications were identified through MEDLINE, EMBASE and Cochrane databases 
and manual searching (June 2013). Pre-specified inclusion criteria identified all studies 
(regardless of catheter used) enrolling TR-HTN patients (SBP ≥ 160 mmHg despite > 3 
anti-hypertensive drugs including a diuretic). Results were presented as weighted 
mean decrease (WMD) in office-based SBP over 6 months. Results: A total of 57 
trials were identified (1 RCT, 11 case control, 16 single arm, 29 case series), yielding 
28 studies (n= 896) for meta-analyses. All were open label and reported significant 
reductions in systolic and diastolic blood pressure. The overall WMD in SBP from all 
studies was -28.1 mmHg (95% CI: -24.5 to -31.6). Analysis of only comparative trials 
produced a reduction from baseline SBP ranging from -31.7 mmHg (95% CI: -25.26 
to -38.14) in the RCT (n= 49) to -26.75 mmHg (95% CI: -22.19 to -31.31) for the pooled 
case control trials (n= 56). cOnclusiOns: Over 6 months, RDN was associated with 
substantial SBP reductions in patients with TR-HTN. However, the majority of eligible 
trials were non-randomised, unblinded and used the Symplicity catheter. This may 
have influenced the magnitude of the treatment effect observed.
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Objectives: The paper is to compare the difference between S-Amlodipine and 
racemic amlodipine by using respective cost-effectiveness analysis MethOds: 
the authors use two head-to-head multi-center, RCT studies’ clinical efficacy data, 
Levamlodiping Besylate tablets (Shiweida® 2.5 mg/day) was selected as test group 
and Amlodipine Besylate tablet (Norvasc® 5mg/day) , as a control group. The blood 
pressure and cost of drug were compared in short-term (8 weeks) and long-term 
(6 months) therapeutic regimes. Results: After 4-8 weeks treatment, there was 
no statistical significant difference in efficacy rate between S-Amlodipine group 
(110cases) and racemic Norvasc group (104 cases) 84.91% vs. 77.45%. The cost of 
reducing 1 mmHg systolic pressure and diastolic pressure in S-Amlodipine group 
was 8.1Yuan (RMB) and 10.5Yuan (RMB), and Norvasc group was 16.9Yuan (RMB) 
and 21.7Yuan (RMB), respectively. The cost of Norvasc is 100% higher than that of 
S-Amlodipine. In the results of 6-month long-term treatment, The cost of reduc-
ing 1 mmHg systolic pressure and diastolic pressure in S-Amlodipine group (124 
cases) was 31Yuan (RMB) and 43Yuan (RMB), and 50Yuan (RMB) and 75Yuan (RMB) 
in Norvasc group (104 cases) , respectively. The cost of Norvasc is 1.62-1.79 times 
higher than that of S-Amlodipine. Meanwhile, the study shows that the cost of 
reducing 1mmHg diastolic blood pressure is much higher than that of reducing 
1mm Hg systolic blood pressure. The adverse reaction of S-Amlodipine group (4.6%) 
is significantly lower than Norvasc group (10.3%). The sensitivity analysis based on 
average price and medium price of two-cluster products in China, the S-Amlodipine 
has more economic value. cOnclusiOns: The domestic product of S-Amlodipine 
is more cost-effectiveness than the original Norvasc product. At present, the market 
volume and value of S-Amlodipine in total CCB market is about 30 percent. The 
authors suggest to do further postmarketing clinical trial and parallel prospective 
pharmacoeconomic evaluation to collect more strong basis of evidence.
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Objectives: The current investigation is aimed to understand the impact of 
medication adherence on reasons for non adherence and adherence and control 
of disease, in diabetes mellitus (DM) with hypertension (HTN) patients Morisky 
medication adherence scale (MMAS). MethOds: In this prospective observational 
study, the inclusion criteria for patients to be enrolled are condition of DM with 
HTN comorbidity and patients taking same medication since last two months. 
Patients with DM along with more than two comorbidities were excluded from 
the study. The demographic details (patient name, age, sex, occupation, patient 
income, address, social history, family history, physical activities) and MMAS, blood 
pressure, fasting blood sugar (FBS) and post lunch blood sugar (PLBS) levels were 
collected from the enrolled patients. Reasons for non adherence were recorded 
from low adherence patients. Results: During the study total 300 patients were 
reviewed of which only 128 (42.66%) patients were enrolled into study among them 
63 (49.3%) were male and 65 (50.7%) were female. According to MMAS, patients 
with high adherence were 39 (30.4%), medium adherence was 30 (23.4%), and low 
adherence was 59 (46%). The reasons for lack of adherence in low adherence patients 
are low socioeconomic status (18%), lack of knowledge about impact of non adher-
ence on medication (16%), followed by patients negligence (12%) and others (13%). 
However the results of all the therapeutic outcomes in the study like average blood 
pressure (mmHg), average FBS (mg/dl) and average PLBS (mg/dl) in high adherence, 
medium adherence and low adherence patients showed variation based on degree 
of adherence. cOnclusiOns: The adequate adherence of medication is the prior 
therapeutic option to control DM with HTN patients.
PCV16
eFFiCaCy OF ayuRVeDiC FORmulaTiOn in THe managemenT OF essenTial 
HyPeRTensiOn
Gopalakrishnan H.1, Acharya S.1, Naik V.2, Nagappa A.N.3
1Muniyal Institute of Ayurveda Medical Sciences, Muniyal, India, 2Manipal Univiersity, Manipal, 
India, 3Department of Pharmacy Management, Manipal College of Pharmaceutical Sciences, 
Manipal University, Manipal, India
